Shortage of Contrast for Imaging Services

Because of a global shortage of iodinated contrast material (Omnipaque) caused by temporary overseas manufacturing disruptions, ChristianaCare is taking steps to preserve supply so that it remains available for the most time-sensitive and urgent patient needs. (Learn more in our frequently asked questions.)

Omnipaque contrast is the most widely used contrast material for CT scans and radiographic examinations at ChristianaCare facilities. It is also used for cardiac imaging and interventions, and in the GI lab, Surgicenter and other settings.

The shortage is expected to last several weeks, and likely into the summer months.

Hospitals and health care organizations worldwide are managing the effects of the shortage and the impact to patient care.

ChristianaCare is making every effort to meet the needs of patients who need this product in their procedures. We are working individually with physicians to prioritize those patients with the most urgent needs.

Wherever possible, we are using alternative contrast material and limiting its use to ensure adequate supplies for time sensitive and emergent exams. It is possible that some elective procedures that use this product will need to be delayed.

ChristianaCare will continue to look for options to minimize disruptions created by the shortage, as we serve our community as expert, caring partners in health.

Learn more in our frequently asked questions (FAQs).

COVID-19: New Visitation Guidelines. Click here for what to expect at ChristianaCare during COVID-19.

ChristianaCare

Shortage of Contrast for Imaging Services

Because of a global shortage of iodinated contrast material (Omnipaque) caused by temporary overseas manufacturing disruptions, ChristianaCare is taking steps to preserve supply so that it remains available for the most time-sensitive and urgent patient needs. (Learn more in our frequently asked questions.)

Omnipaque contrast is the most widely used contrast material for CT scans and radiographic examinations at ChristianaCare facilities. It is also used for cardiac imaging and interventions, and in the GI lab, Surgicenter and other settings.

The shortage is expected to last several weeks, and likely into the summer months.

Hospitals and health care organizations worldwide are managing the effects of the shortage and the impact to patient care.

ChristianaCare is making every effort to meet the needs of patients who need this product in their procedures. We are working individually with physicians to prioritize those patients with the most urgent needs.

Wherever possible, we are using alternative contrast material and limiting its use to ensure adequate supplies for time sensitive and emergent exams. It is possible that some elective procedures that use this product will need to be delayed.

ChristianaCare will continue to look for options to minimize disruptions created by the shortage, as we serve our community as expert, caring partners in health.

Learn more in our frequently asked questions (FAQs).

COVID-19: New Visitation Guidelines. Click here for what to expect at ChristianaCare during COVID-19.

Breast Cancer Research Program at the
Helen F. Graham Cancer Center
& Research Institute

Key Publications

Frizzled7 antibody-functionalized nanoshells enable multivalent binding for Wnt signaling inhibition in triple negative breast cancer cells Riley RS, Day ES.. Small. 2017; 13(26): 1700544.

Antibody-nanoparticle conjugates to improve the sensitivity of ELISA-based detection methods Billingsley MM, Riley RS, Day ES.. PLOS ONE. 2017; 12(5); e0177592.

Nanoshell-mediated photothermal therapy can enhance chemotherapy in inflammatory breast cancer cells Fay BL, Melamed JR, Day ES.. International Journal of Nanomedicine. 2015; 10: 6931-6941.

Your Patient Got a Dense Breast Notifi cation with Her Mammogram Report: What Are You Supposed to Do? Dickson-Witmer, D. Sabesan, A. Del Med J .March 2018, 90(3) 76-81.

ACS CRP Dissemination and Implementation Committee issues call for participants in pilot project. Dickson-Witmer D, Blair S, Boughey JC. Bull Am Coll Surg. 2017 Jun;102(6):48-50. PMID: 28885810

Dense Breasts: What Do Our Patients Need to Be Told and Why?Throckmorton AD, Rhodes DJ, Hughes KS,, Degnim AC, Dickson-Witmer,D Ann Surg Oncol. 2016 Oct;23(10):3119-27PMID: 27401446.

Dissemination and implementation: Translating cancer guidelines and clinical trial outcomes into everyday practice. Wilke LG, Dickson-Witmer D, Boughey JC. Bull Am Coll Surg. 2016 Feb;101(2):33-4. No abstract available.PMID: 26995861

Performance and Practice Guideline for the Use of Neoadjuvant Systemic Therapy in the Management of Breast Cancer.Holmes D, Colfry A, Czerniecki B, Dickson-Witmer D, Francisco Espinel C, Feldman E, Gallagher K, Greenup R, Herrmann V, Kuerer H, Malik M, Manahan E, O’Neill J, Patel M, Sebastian M, Wheeler A, Kass R.Ann Surg Oncol. 2015 Oct;22(10):3184-90. doi: 10.1245/s10434-015-4753-3. Epub 2015 Jul 30. Review. PMID: 26224406

Standardization of pathologic evaluation and reporting of postneoadjuvant specimens in clinical trials of breast cancer: recommendations from an international working group. Provenzano E, Bossuyt V, Viale G, Cameron D, Badve S, Denkert C, MacGrogan G, Penault-Llorca F, Boughey J, Curigliano G, Dixon JM, Esserman L, astner G, Kuehn T, Peintinger F, von Minckwitz G, White J, Yang W, Symmans WF, Dickson-Witmer, D; Residual Disease Characterization Working Group of the Breast International Group-North American Breast Cancer Group Collaboration. Mod Pathol. 2015 Sep;28(9):1185-201. doi: 10.1038/modpathol.2015.74. Epub 2015 Jul 24.PMID: 26205180

Clinical Performance of Synthesized Two-dimensional Mammography Combined with Tomosynthesis in a Large Screening Population. Aujero, M., Holt, JS. Radiology. April 2017,283(1) 70-76.

Fabrication of Complex Functional Biomaterial Microstructures by In situ Photopolymerization and Photodegradation,PJ LeValley, B Noren, PM Kharkar, AM Kloxin, JC Gatlin, J Oakey, ACS Biomaterials Science & Engineering, In Press. DOI: 10.1021/acsbiomaterials.8b00350

Design of functionalized cyclic peptides through orthogonal click reactions for cell culture and targeting applications, PJ LeValley, EO Ovadia, CA Bresette, LA Sawicki, E Maverakis, S Bai, AM Kloxin, “ Chemical Communications, 54, 6923-6926, 2018. DOI: 10.1039/C8CC03218A.

Design of Synthetic Extracellular Matrices for Probing Breast Cancer Cell Growth Using Robust Cyctocompatible Nucleophilic Thiol-yne Addition Chemistry LJ Macdougall, KL Wiley, AM Kloxin, AP Dove, Biomaterials, 178, 435-447, 2018. DOI: 10.1016/j.biomaterials.2018.04.046.

Designing photopolymerized synthetic matrices for three-dimensional culture and differentiation of induced pluripotent stem cells. EO Ovadia, DW Colby, AM KloxinBiomaterials Science, 6, 1358-1370, 2018. DOI: 10.1039/c8bm00099a

Fast, Irreversible Modification of Cysteines through Strain Releasing Conjugate Additions of Cyclopropenyl Ketones NJ Smith, K Rohlfing, LA Sawicki, PM Kharkar, SJ Boyd, AM Kloxin, JM Fox, Organic & Biomolecular Chemistry, 16, 2164-2169, 2018. DOI: 10.1039/C8OB00166A

Techniques for the isolation and identification of proteins secreted by cells cultured within synthetic extracellular matrices LA Sawicki, LH Choe, KL Wiley, KH Lee, AM Kloxin, ACS Biomaterials Science and Engineering, 4, 836-845, 2018, 2018.  DOI: 1021/acsbiomaterials.7b00647

Image-Guided, Laser-Based Fabrication of Vascular-Derived Microfluidic Networks.” Journal of Visualized Experiments . K.A. Heintz, D. Mayerich, & J.H. Slater. “. 2017. [JoVE Video]

Fabrication of 3D Biomimetic Microfluidic Networks in Hydrogels K.A. Heintz, M.E. Bregenzer, J.L. Niemczyk, K.H. Lee, J.L. West, & J.H. Slater. Advanced Healthcare Materials. 2017.

A Strategy Toward Icetexane Natural Products Moon, DJ; Al-Amin, M;. Lewis, RS. ; Arnold, KM; Glenn P. Yap, A.; Sims-Mourtada, J; Chain, WJ;. – Eur. J. Org. Chem. 0.1002/ejoc.20180070.

The impact of radiation on the tumor microenvironment: effect of dose and fractionation schedules. Arnold, KM, Flynn, NJ, Raben, A, Romak, L, Yu, Y, Dicker, AP, Mourtada, F, Sims-Mourtada, J. 2018 Mar 9;11:1179064418761639. doi: 10.1177/1179064418761639. eCollection 2018. Review.

Co-activation of Hedgehog and WNT signaling pathways is associated with poor outcomes in triple negative breast cancer. Arnold, KM, Pohlig, RT., Sims-Mourtada, J. Oncology Letters 14, 5285-5292. https://doi.org/10.3892/ol.2017.6874.

The Multifaceted Roles of B Cells in Solid Tumors: Emerging Treatment Opportunities. Flynn, NJ., Somasundrum, R., Arnold, KM., Sims-Mourtada, J.. Target Oncol. 2017 Mar 9. doi: 10.1007/s11523-017-0481-x. PMID: 28281220

Obesity in breast cancer: Do age, race and subtype matter? Arnold, K.M., Flynn, N.J., Sims-Mourtada, J. Cancer Res Ther 2016, 2( 5) :021.

Activation of Inflammatory Responses Correlate With Hedgehog Activation and Precede Expansion of Cancer Stem-Like Cells in an Animal Model of Residual Triple Negative Breast Cancer after Neoadjuvant Chemotherapy.Arnold, K.M, Flynn, N. J, Sims-Mourtada, J. Cancer Studies and Molecular Medicine. 12/2015; 2(2):80-86. PMID: 25674014

Cancer Research Program
Helen F. Graham Cancer Center & Research Institute
4701 Ogletown-Stanton Road, Suite 2200, Newark, DE 19713 directions
For more information, call 302-623-4450 or e-mail us.